Cyclerion Therapeutics, Inc. (CYCN)
| Previous close | 2.8500 |
| Open | 2.8400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.8400 - 2.8400 |
| 52-week range | 1.7500 - 6.7500 |
| Volume | |
| Avg. volume | 2,790 |
| Market cap | 8.008M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.1800 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider Monkey12 Best Biotech Penny Stocks to Invest In
In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]
GlobeNewswireCyclerion Appoints Regina Graul, Ph.D., as President
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for
- GlobeNewswire
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (G
